Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2026
- Completed Enrollment in LOTUS, a Phase 2b Trial of Zelicapavir in Pediatric Patients with Respiratory Syncytial Virus (RSV); Topline Data Expected in 1Q 2027
- Initiated Dosing in RESOLVE, a Phase 2b/3 Trial of Zelicapavir in Adult Patients at High-Risk of Severe RSV Outcomes; Topline Phase 2b Data Expected in 2027
- Topline Data from Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, Now Expected in 1Q 2027
-
Investigational New Drug (IND) Application Filing for EDP-903, an Oral,
Once-Daily STAT6 Inhibitor, Now Expected in 2Q 2027 - Selected MRGPRX2 Development Candidate EPS-5336 for the Treatment of Mast Cell-Driven Diseases Including Migraine; IND Filing Targeted for 4Q 2027
-
Announced the Planned Retirement of Longstanding President and Chief Executive Officer,
Jay R. Luly , Ph.D. byFebruary 2027 , and the Promotion ofTara L. Kieffer , Ph.D. to Chief Operating Officer -
Cash and Marketable Securities Totaling
$194.5 Million atSeptember 30, 2026 , as well as Continuing Retained Royalties, with Cash Runway Expected to Fund Operations into Fiscal 2029
“During fiscal 2026 we made significant progress across our virology and immunology portfolios. In RSV, we completed enrollment in LOTUS, a Phase 2b trial of zelicapavir in pediatric patients, with topline data expected in the first quarter of 2027. We also began dosing patients in RESOLVE, a Phase 2b/3 trial of zelicapavir in adults at high risk of severe disease and anticipate reporting data from the Phase 2b portion in 2027,” said
Fiscal Fourth Quarter and Year-Ended
Total revenue was
A portion (54.5%) of Enanta’s ongoing royalty revenue from AbbVie’s net sales of MAVYRET®/MAVIRET® is paid to OMERS, one of Canada’s largest defined benefit pension plans, pursuant to a royalty sale transaction affecting royalties earned after
Research and development expenses were
General and administrative expenses totaled
Interest and investment income, net, totaled
Enanta recorded an income tax benefit of less than
Net loss for the three months ended
Enanta’s cash, cash equivalents and marketable securities totaled
Virology
Enanta’s virology pipeline includes the leading portfolio of RSV treatments in clinical development, consisting of zelicapavir, a once-daily N-protein inhibitor, and EDP-323, a once-daily L-protein inhibitor, both of which received Fast Track designation from the
- Enrollment is completed in LOTUS, a Phase 2b trial of zelicapavir in pediatric patients with RSV. LOTUS is designed to evaluate time to complete resolution of RSV signs and symptoms as measured by the RESOLVE-P clinical scoring scale, together with the safety and antiviral activity of zelicapavir. Topline data from LOTUS are expected in the first quarter of 2027.
- Enrollment is ongoing in RESOLVE, a Phase 2b/3 trial of zelicapavir in adults at high-risk for severe RSV disease, including patients aged 75 years or older and those with chronic obstructive pulmonary disease or congestive heart failure. The trial will evaluate time to complete resolution of 13 RSV symptoms as measured by RiiQ™, while secondary endpoints include reduction in hospitalization rate, additional clinical efficacy measures, virology and safety. Topline data from the Phase 2b portion of RESOLVE are expected in 2027.
Immunology
Enanta’s immunology pipeline is focused on designing and developing highly potent and selective oral inhibitors for the treatment of inflammatory diseases by targeting key drivers of the type 2 immune response.
- Enanta’s lead immunology candidate, EDP-978, is a potent and selective, oral once-daily KIT inhibitor in development for the treatment of chronic urticaria and potentially other mast cell-mediated diseases. A randomized, double-blind, placebo-controlled, first-in-human Phase 1 clinical trial is ongoing and the Company expects to complete dosing by year-end 2026. Enanta now expects to report topline data from the trial in the first quarter of 2027.
- Enanta’s second immunology candidate, EDP-903, is a potent and selective, oral once-daily STAT6 inhibitor in development for the treatment of atopic dermatitis and other diseases currently treated by dupilumab. While IND-enabling activities are complete, due to a delay in drug manufacturing, the Company is now targeting an IND filing in the second quarter of 2027.
- Enanta’s third immunology program targets MRGPRX2, a non-canonical G-Protein-Coupled-Receptor (GPCR) expressed predominantly on mast cells, as well as peripheral neurons. Inhibiting MRGPRX2 may have potential to address multiple mast-cell driven diseases, as well as migraine. The Company selected EPS-5336 as a development candidate. EPS-5336 is a potent inhibitor of MRGPRX2 signaling in vitro and in vivo, with sub-nanomolar potency (EC50 of 0.2-0.6nM) in cellular assays via the preferred noncompetitive mechanism of inhibition. EPS-5336 also prevents skin mast cell activation in humanized MRGPRX2 mouse models. Further, EPS-5336 shows potent activity across multiple MRGPRX2 agonists and inhibits MRGPRX2-induced degranulation in migraine-relevant meningeal mast cells. EPS-5336 is highly selective for MRGPRX2 versus other GPCRs. EPS-5336 also demonstrates favorable in vitro and in vivo ADME properties, supportive of once-daily dosing potential. The Company expects to file an IND in the fourth quarter of 2027.
Corporate
-
In
October 2026 , Enanta announced thatJay R. Luly , Ph.D., age 70, will retire as President and Chief Executive Officer, byFebruary 1, 2027 , following 23 years of leadership with the Company. The Board of Directors has initiated a comprehensive search forDr. Luly's successor, considering both internal and external candidates.Dr. Luly is expected to continue to serve as a strategic advisor for the remainder of 2027 to support a smooth and orderly transition. The Company also announced the appointment ofTara L. Kieffer , Ph.D., to the newly created role of Chief Operating Officer. After a 16-year career of advancement at Vertex Pharmaceuticals in research, clinical development, integrated program management and business development,Dr. Kieffer joined Enanta in 2020, most recently serving as the Company’s Chief Product Strategy Officer. -
In
August 2025 , Enanta filed a patent infringement action in the Unified Patent Court (UPC) of the European Union against Pfizer Inc. and certain of its subsidiaries, seeking a determination of liability for infringement of European Patent No. EP 4 051 265 (the ’265 Patent) in connection with Pfizer’s manufacture, use, and sale of Paxlovid™ (nirmatrelvir tablets; ritonavir tablets) in the 18 EU member states participating in the UPC. Pfizer counterclaimed for revocation of the ’265 Patent. A hearing on the infringement action and counterclaim for revocation was held inSeptember 2026 . In October, the UPC released its decision concluding that the ’265 Patent is invalid. The UPC also determined that the infringement action was unfounded in light of its decision on validity. In the separate opposition proceeding filed by Pfizer with theEuropean Patent Office (EPO) against the ’265 Patent, the EPO has set a hearing date inApril 2027 . - In September, Enanta conducted a strategic assessment of its resource allocation and operating structure to ensure alignment with its current priorities and long-term objectives. As a result of this review, the Company implemented targeted workforce reductions across the organization to increase operational efficiency, focus resources on its highest-priority opportunities and extend financial flexibility. In connection with these actions, Enanta’s workforce was reduced by approximately one-third.
-
Enanta will present at the
Jefferies Global Healthcare Conference inLondon onNovember 18, 2026 , and at the 9th AnnualEvercore Healthcare Conference onDecember 2, 2026 . -
Enanta plans to issue its fiscal first quarter 2027 financial results press release on
February 8, 2027 .
About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and immunological diseases. In virology, Enanta’s clinical programs are focused on the development of first-in-disease and best-in-disease treatments for respiratory syncytial virus (RSV). The Company’s immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, with KIT, STAT6 and MRGPRX2 inhibition.
Glecaprevir, a protease inhibitor discovered by Enanta, is part of the only treatment approved for curing both acute and chronic hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations. Please visit www.enanta.com for more information.
Forward Looking Statements
This press release contains forward-looking statements, including statements with respect to the timeline and prospects for advancement of Enanta’s clinical programs in RSV and KIT inhibition and its preclinical immunology programs, including its programs targeting STAT6 and MRGPRX2 inhibition; the expected timing of completion of dosing and reporting of topline data from Enanta’s LOTUS and RESOLVE clinical trials; the potential of zelicapavir and Enanta’s immunology product candidates to address unmet medical needs and achieve best-in-class or best-in-disease profiles; the sufficiency of Enanta’s cash, cash equivalents and marketable securities, together with its retained portion of future royalty revenue, to fund its operations into fiscal 2029; the anticipated benefits of Enanta’s September 2026 workforce reduction; and Enanta’s planned leadership transition. Statements that are not historical facts are based on management’s current expectations, estimates, forecasts and projections about Enanta’s business and the industry in which it operates and management’s beliefs and assumptions. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors and risks that may affect actual results include: the impact of development, regulatory and marketing efforts of others with respect to vaccines and competitive treatments for RSV; the discovery and development risks of Enanta’s programs in virology and immunology; risks of delays in patient enrollment, clinical trial conduct, drug manufacturing and IND-enabling activities; Enanta’s ability to partner its RSV or other programs; Enanta’s dependence on royalty revenue from AbbVie’s sales of MAVYRET®/MAVIRET®, a portion of which is paid to OMERS; Enanta’s need for, and ability to obtain, additional funding, and the length of its cash runway; Enanta’s need to attract and retain senior management and key research and development personnel, including risks associated with its leadership transition; Enanta’s need to obtain and maintain patent protection for its product candidates and avoid potential infringement of the intellectual property rights of others; and other risk factors described or referred to in “Risk Factors” in Enanta’s Form 10-K for the fiscal year ended September 30, 2025, as updated by periodic reports subsequently filed with the Securities and Exchange Commission. Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Enanta undertakes no obligation to update or revise these statements, except as may be required by law.
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||||||
| UNAUDITED | |||||||||||||||||||
| (in thousands, except per share amounts) | |||||||||||||||||||
| Three Months Ended | Twelve Months Ended | ||||||||||||||||||
|
|
2026 |
|
|
|
2025 |
|
|
|
2026 |
|
|
|
2025 |
|
|||||
| Revenue |
$ |
12,868 |
|
$ |
15,125 |
|
$ |
63,001 |
|
$ |
65,324 |
|
|||||||
| Operating expenses | |||||||||||||||||||
| Research and development |
|
26,118 |
|
|
23,809 |
|
|
88,546 |
|
|
106,740 |
|
|||||||
| General and administrative |
|
8,789 |
|
|
9,702 |
|
|
36,835 |
|
|
43,933 |
|
|||||||
| Total operating expenses |
|
34,907 |
|
|
33,511 |
|
|
125,381 |
|
|
150,673 |
|
|||||||
| Loss from operations |
|
(22,039 |
) |
|
(18,386 |
) |
|
(62,380 |
) |
|
(85,349 |
) |
|||||||
| Interest expense |
|
(3,545 |
) |
|
(2,387 |
) |
|
(14,074 |
) |
|
(7,681 |
) |
|||||||
| Interest and investment income, net |
|
1,818 |
|
|
2,066 |
|
|
8,225 |
|
|
9,442 |
|
|||||||
| Change in fair value of Series 1 nonconvertible preferred stock |
|
21 |
|
|
39 |
|
|
21 |
|
|
39 |
|
|||||||
| Loss before income taxes |
|
(23,745 |
) |
|
(18,668 |
) |
|
(68,208 |
) |
|
(83,549 |
) |
|||||||
| Income tax benefit (expense) |
|
27 |
|
|
(32 |
) |
|
(40 |
) |
|
1,660 |
|
|||||||
| Net loss |
$ |
(23,718 |
) |
$ |
(18,700 |
) |
$ |
(68,248 |
) |
$ |
(81,889 |
) |
|||||||
| Net loss per share | |||||||||||||||||||
| Basic |
$ |
(0.81 |
) |
$ |
(0.87 |
) |
$ |
(2.35 |
) |
$ |
(3.84 |
) |
|||||||
| Diluted |
$ |
(0.81 |
) |
$ |
(0.87 |
) |
$ |
(2.35 |
) |
$ |
(3.84 |
) |
|||||||
| Weighted average common shares outstanding | |||||||||||||||||||
| Basic |
|
29,127 |
|
|
21,380 |
|
|
29,001 |
|
|
21,336 |
|
|||||||
| Diluted |
|
29,127 |
|
|
21,380 |
|
|
29,001 |
|
|
21,336 |
|
|||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
| UNAUDITED | ||||||||
| (in thousands) | ||||||||
|
|
2026 |
|
|
2025 |
||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents |
$ |
20,272 |
$ |
32,298 |
||||
| Short-term marketable securities |
|
174,241 |
|
156,566 |
||||
| Accounts receivable |
|
5,855 |
|
6,882 |
||||
| Prepaid expenses and other current assets |
|
5,626 |
|
8,590 |
||||
| Total current assets |
|
205,994 |
|
204,336 |
||||
| Property and equipment, net |
|
30,858 |
|
35,395 |
||||
| Operating lease, right-of-use assets |
|
35,249 |
|
37,549 |
||||
| Long-term restricted cash |
|
3,360 |
|
3,360 |
||||
| Other long-term assets |
|
116 |
|
92 |
||||
| Total assets |
$ |
275,577 |
$ |
280,732 |
||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable |
$ |
2,750 |
$ |
1,948 |
||||
| Accrued expenses and other current liabilities |
|
14,685 |
|
12,751 |
||||
| Liability related to the sale of future royalties |
|
32,968 |
|
30,710 |
||||
| Operating lease liabilities |
|
4,057 |
|
3,146 |
||||
| Total current liabilities |
|
54,460 |
|
48,555 |
||||
| Liability related to the sale of future royalties, net of current portion |
|
88,637 |
|
111,132 |
||||
| Operating lease liabilities, net of current portion |
|
50,700 |
|
54,757 |
||||
| Series 1 nonconvertible preferred stock |
|
1,290 |
|
1,311 |
||||
| Other long-term liabilities |
|
295 |
|
260 |
||||
| Total liabilities |
|
195,382 |
|
216,015 |
||||
| Total stockholders' equity |
|
80,195 |
|
64,717 |
||||
| Total liabilities and stockholders' equity |
$ |
275,577 |
$ |
280,732 |
||||
View source version on businesswire.com: https://www.businesswire.com/news/home/20261116633822/en/
Media and Investors:
617-744-3848
jviera@enanta.com
Source:
- Print Page Print Page
- Email Alerts Email Alerts
- RSS Feeds RSS Feeds
- Contact IR Contact IR